Programa de Pós-Graduação em Endocrinologia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brasil.
Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brasil.
Arch Endocrinol Metab. 2021 Nov 1;64(6):639-653. doi: 10.20945/2359-3997000000306. Epub 2020 Nov 9.
Statins are among the most widely prescribed medicines in the world and have proved their value in reducing cardiovascular events and mortality. Many patients report adverse effects that lead to interruption of treatment. This review aims to individualize statin treatment, considering efficacy for reducing cardiovascular risk and safety, in the setting of specific diseases, to minimize the side effects and improve compliance. We gathered evidence that may help clinicians to choose specific statins in different clinical situations, such as the risk of new diabetes, chronic kidney disease, liver disease, human immunodeficiency virus infection, organ transplant, heart failure and elderly people. Efficacy of statins is well established in a large number of clinical conditions. Therefore, main objective is to revise statin in specific clinical settings, based on pharmacokinetics, safety, drug metabolism and interactions to provide the best choice in different clinical scenarios.
他汀类药物是世界上应用最广泛的药物之一，已被证明可降低心血管事件和死亡率。许多患者报告称出现不良反应，导致治疗中断。本综述旨在根据特定疾病考虑降低心血管风险和安全性的疗效来个体化他汀类药物治疗，以最大程度减少副作用并提高依从性。我们收集了可能有助于临床医生在不同临床情况下选择特定他汀类药物的证据，例如新发糖尿病、慢性肾脏病、肝病、人类免疫缺陷病毒感染、器官移植、心力衰竭和老年人的风险。他汀类药物在大量临床情况下的疗效已得到充分证实。因此，主要目标是根据药代动力学、安全性、药物代谢和相互作用在特定临床环境中修订他汀类药物，为不同临床情况下提供最佳选择。
